Boston Scientific (NYSE: BSX) CEO gifts 386,755 shares to irrevocable trust

Rhea-AI Filing Summary

Boston Scientific Chairman, President & CEO Michael F. Mahoney reported a large charitable-style transfer of stock. He made a bona fide gift of 386,755 shares of Boston Scientific common stock on May 28, 2026 to The Michael F. Mahoney Term Irrevocable Trust - 2026, which is administered by an independent trustee.

After this transaction, Mahoney continues to hold 1,403,784 shares of Boston Scientific common stock directly. The gift is a non-market disposition with no sale proceeds reported, meaning it does not reflect open-market buying or selling activity in the stock.

Insider Trade Summary

386,755 shares gifted

Mixed 2 txns

Insider Mahoney Michael F

Role Chairman, President & CEO

Type	Security	Shares	Price	Value
Gift	Common Stock	386,755	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 0 shares (Indirect, By Trust); Common Stock — 1,403,784 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares gifted: 386,755 shares Direct holdings after transaction: 1,403,784 shares Gift price per share: $0.00 per share +1 more

4 metrics

Shares gifted 386,755 shares Bona fide gift of common stock on May 28, 2026

Direct holdings after transaction 1,403,784 shares Common stock directly owned after reported transactions

Gift price per share $0.00 per share Reported transaction price for gifted shares

Indirect trust position after gift 0 shares Trust holdings of common stock following the gift

Key Terms

bona fide gift, Form 4, indirect ownership, Term Irrevocable Trust, +1 more

5 terms

bona fide gift financial

"transaction_code_description: "Bona fide gift" for 386,755 shares"

A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

indirect ownership financial

"direct_or_indirect: "I", nature_of_ownership: "By Trust""

Term Irrevocable Trust financial

"The Michael F. Mahoney Term Irrevocable Trust - 2026"

Common Stock financial

"security_title: "Common Stock" for both transactions"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mahoney Michael F

(Last) (First) (Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH MASSACHUSETTS 01752-1234

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman, President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/28/2026		G(1)		386,755	D	$0.0000	0.0000	I	By Trust
Common Stock								1,403,784	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction involved a gift of securities by the reporting person to The Michael F. Mahoney Term Irrevocable Trust - 2026, which is administered by an independent trustee.

	/s/ Susan Thompson, Attorney-in-Fact	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Boston Scientific (BSX) CEO Michael Mahoney report in this Form 4?

Michael F. Mahoney reported a bona fide gift of 386,755 Boston Scientific common shares to an irrevocable trust. The filing also shows he continues to hold 1,403,784 shares directly after the transaction.

How many Boston Scientific (BSX) shares did the CEO gift?

Michael F. Mahoney gifted 386,755 shares of Boston Scientific common stock. The transfer is coded as a bona fide gift, meaning it was not an open-market sale and involved no per-share transaction price.

Does Michael Mahoney still own Boston Scientific (BSX) shares after the gift?

Yes. After the reported gift, Michael F. Mahoney directly owns 1,403,784 shares of Boston Scientific common stock. The gifted shares were held indirectly by a trust, which shows zero shares following the transfer.

Who received the gifted Boston Scientific (BSX) shares from the CEO?

The 386,755 gifted shares were transferred to The Michael F. Mahoney Term Irrevocable Trust - 2026. According to the filing footnote, this trust is administered by an independent trustee, indicating separate administration from Mahoney personally.

Was the Boston Scientific (BSX) CEO’s Form 4 transaction a market sale?

No. The Form 4 characterizes the transaction as a bona fide gift with a per-share price of $0.00. This means it was a non-market transfer, not an open-market sale or purchase on a stock exchange.